Glen Harbor Capital Management’s Supernus Pharmaceuticals SUPN Stock Holding History

Glen Harbor Capital Management’s Portfolio SUPN Stock Details SUPN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	$145K	Buy	5,264 +192	+4%	+$5.69K	﹤0.01%	1101
2019 Q2	$168K	Hold	5,072	–	–	﹤0.01%	1062
2019 Q1	$178K	Hold	5,072	–	–	﹤0.01%	1023
2018 Q4	$168K	Hold	5,072	–	–	﹤0.01%	996
2018 Q3	$255K	Buy	5,072 +928	+22%	+$45.8K	0.01%	972
2018 Q2	$248K	Hold	4,144	–	–	0.01%	902
2018 Q1	$190K	Buy	4,144 +176	+4%	+$7.34K	﹤0.01%	983
2017 Q4	$158K	Buy	3,968 +832	+27%	+$32.9K	﹤0.01%	1051
2017 Q3	$125K	Buy	3,136 +416	+15%	+$18K	﹤0.01%	1067
2017 Q2	$117K	Buy	2,720 +1,280	+89%	+$45.6K	﹤0.01%	1046
2017 Q1	$45K	Buy	1,440 +144	+11%	+$3.86K	﹤0.01%	1141
2016 Q4	$33K	Buy	+1,296	New	+$29K	﹤0.01%	1147

Other funds holding SUPN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

RHJA

Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return

Fuller & Thaler Asset Management San Mateo, California $29.7B AUM 43.33% 1-Year Est. Return

ACM

Ashford Capital Management Wilmington, Delaware $809M AUM 35.1% 1-Year Est. Return

Glen Harbor Capital Management's SUPN Position: Q3 2019 in Review

Glen Harbor Capital Management increased its Supernus Pharmaceuticals (SUPN) stake by 3.8% in Q3 2019, buying an estimated $5.69K and bringing the position to 5,264 shares worth $145K. The position accounts for ﹤0.01% of the portfolio, ranked #1101.

Glen Harbor Capital Management first reported a position in SUPN in Q4 2016 and has held it in 12 quarters since. The position peaked at $255K in Q3 2018. 243 funds tracked by Wall St. Rank hold SUPN as of Q3 2019.

Glen Harbor Capital Management held 5,264 shares of Supernus Pharmaceuticals worth $145K as of Q3 2019.
Glen Harbor Capital Management bought 192 Supernus Pharmaceuticals shares in Q3 2019, an estimated $5.69K.
Supernus Pharmaceuticals made up ﹤0.01% of Glen Harbor Capital Management's portfolio in Q3 2019, its #1101 holding.
Glen Harbor Capital Management first reported a position in Supernus Pharmaceuticals in Q4 2016 and has held it in 12 quarters since.
Glen Harbor Capital Management's Supernus Pharmaceuticals position peaked at $255K in Q3 2018.
243 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q3 2019.

Based on Glen Harbor Capital Management's 13F filing for Q3 2019, filed 13 Nov 2019.